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The greater understanding of pathophysiology and behavior of systemic vasculitis, together
with the development of therapeutic regimens with increasingly better safety and efﬁ-
cacy proﬁles, dramatically changed the prognosis of patients diagnosed with these clinical
entities. Recently, the use of rituximab in the treatment of patients with ANCA-associated
vasculitis in randomized clinical trials showed an important alternative in selected cases,
especially patients refractory or intolerant to standard therapy with cyclophosphamide
and  corticosteroids. This article presents the report of seven cases of systemic vasculitis
successfully treated with rituximab.
© 2015 Elsevier Editora Ltda. All rights reserved.
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diagnosticados com essas entidades clínicas. Recentemente, o emprego do rituximabe
no  tratamento de pacientes com vasculites ANCA associadas em ensaios clínicos ran-
domizados se mostrou uma opc¸ão importante em casos selecionados, especialmente
pacientes refratários ou intolerantes à terapia-padrão com ciclofosfamida e corticosteroides.
O  presente artigo traz o relato de sete casos de vasculites sistêmicas com tratamento bem-
sucedido com rituximabe.
© 2015 Elsevier Editora Ltda. Todos os direitos reservados.Introduction
The introduction of glucocorticoids and, later, of cyclophos-
phamide (CYC) in inducing remission of systemic vasculitis
(SV) dramatically changed the prognosis of these patients,
resulting in symptomatic improvement, high rates of remis-
sion and in increased survival.1,2 However, a signiﬁcant
portion of patients remains refractory or intolerant to con-
ventional therapies,3 justifying the growing interest in new
safer and more  effective therapeutic options. Recent evidence
points to a crucial role of B lymphocytes in the development
of SV.4 Rituximab (RTX) is a chimeric anti-CD20+ B cell mono-
clonal antibody widely used in B cell lymphomas, and more
recently has been used for various autoimmune conditions in
selected cases.
We  report seven cases of patients diagnosed with SV
treated successfully with RTX.
Case  report
Patient  1
Male, 46, with fever, weight loss, severe pulmonary vasculi-
tis (Fig. 1), pauci-immune glomerulonephritis and neuropathy
of lower limbs, with Birmingham Vasculitis Activity Score
(BVAS) = 20 and ANCA-negative. Treated under a diagnosis of
microscopic polyangiitis (MPA), subjected to pulse therapy
with methylprednisolone (MP) followed by cyclophosphamide
associated with prednisone 40 mg/day. The patient developed
hyperglycemia and liver toxicity; thus, this treatment was
suspended, with the introduction of weekly doses of RTX
375 mg/m2 for 4 weeks. After a year of treatment, the patient
achieved complete remission without maintenance therapy.
Patient  2
Female, 31, presenting edema and ﬁxed cyanosis of extremi-
ties, polyarthralgia, subcutaneous nodules, limb ischemia and
acute respiratory failure (BVAS = 15), with a diagnosis of pol-
yarteritis nodosa (PAN) and HBsAg positive for 6 years. Skin
biopsy showed ﬁbrinoid necrosis and medium-caliber vessel
inﬁltration. Subjected to pulse therapy with MP and CYC with
poor response. Treatment was started with two fortnightly
doses of RTX 1 g, with dramatic improvement. Treated with
a maintanance infusion of RTX after 6 months, maintaining
complete remission without steroids.Patient  3
Male, 56, admitted with arthritis, nephritis, retinal vasculi-
tis, pulmonary nodules and peripheral neuropathy (BVAS = 17).
With a diagnosis of granulomatosis with polyangiitis (GPA) for
3 years with cANCA 1/40, refractory to 7 pulses of MP  and
CYC. After rescue therapy with 4 weekly infusions of RTX
375 mg/m2, the patient showed complete remission of the dis-
ease for three years, with maintenance therapy with RTX every
6 months.
Patient  4
Female, 47, with ongoing fever, weight loss, hearing loss, pal-
pable purpura, glomerulonephritis and hemoptysis for the
duration of 3 years (BVAS = 38 at admission), with a diag-
nosis of GPA. A chest CT scan revealed multiple pulmonary
cavitations. Ancillary and therapeutic tests negative for tuber-
culosis, with subsequent weekly RTX infusion for 4 weeks. The
patient remains in complete remission after 1 year, without
maintenance therapy.
Patient  5
Male, 26, with an early weight loss, arthritis, sinusitis, conjunc-
tivitis and abdominal pain for 5 months (BVAS = 12), pANCA
1/20. After ruling out differential diagnoses, the patient was
treated as with GPA, beginning with two biweekly infusions
of RTX. A maintenance schedule with half-yearly infusions of
RTX was chosen.
Patient  6
Male, 24, with manifestations of nephritis and with a biopsy
revealing pauci-immune glomerulonephritis, compatible with
a diagnosis of MPA,  refractory to multiple pulses of MP and
CYC over 5 years. A scheme of 4 weekly infusions of RTX was
started, with early BVAS = 12, achieving complete remission;
as maintenance, half-yearly infusions were scheduled.
Patient  7
Female, 45, with weight loss, arthritis and mononeuritis mul-
tiplex over 5 years, with p-ANCA 1/40. The patient received a
diagnosis of MPA, and started a weekly RTX infusion schedule
for 4 weeks, resulting in complete remission.
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Fig. 1 – Chest CT coronal reconstruction of patient 1. (A) View prior to treatment, showing diffuse opacities compatible with
diffuse alveolar hemorrhageand pulmonary capillaritis. (B) View after rituximab therapy, showing regression of lesions.
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ystemic vasculitides (SV) are a heterogeneous group of
onditions whose main landmark is a primary inﬂamma-
ion and damage to blood vessels with subsequent tissue
schemia and/or vascular hemorrhage. Many  are the condi-
ions that ﬁt this clinical-pathological proﬁle, affecting vessels
f different sizes in different organic systems with variable
ntensity.5
Among the cases described, a diagnosis of MPA for patients
, 6 and 7 were proposed, and patients 3, 4 and 5 were
iagnosed with GPA, while patient 2 was treated under the
ypothesis of PAN. Although GPA and MPA are classically
eferred to as ANCA-associated vasculitides (AAV), patients 1,
 and 6 had a negative ANCA, a phenotype also referred to as
eronegative vasculitis by some authors, with involvement of
0% of cases.5
SVs are well recognized for their potential severity, with
n often accelerated evolution and resulting in death if not
reated properly. Prior to the introduction of effective therapies
or SV, the ﬁve-year survival rate was around 10%, in contrast
o over 80% reported in the literature after the introduction of
YC and corticosteroids.1,2
The treatment with CYC, however, is not without seri-
us adverse events, such as myelosuppression (2%), infections
46%), neoplasms (2.8%), and infertility (57%).6 Furthermore,
he 5-year recurrence risk for patients treated appropriately is
8%.3 The current scenario has motivated a growing interest in
ew therapeutic agents for SV as drugs of choice or alternative
edications in carefully selected cases.
Evidence supports a well-established pathogenic role of B
ells in the development of autoimmune diseases. Among the
roposed mechanisms, is the fact that B cells are precursors
f ANCA-producing plasma cells, besides the production of
ytokines critical for the development of T-cell hyperactivity
nd stimulating proliferation and activation of neutrophils.4These factors constituted the premise for experimental stud-
ies evaluating the therapeutic response of patients with SV
undergoing infusion of RTX.
RTX is a chimeric anti-CD20+ B-cell monoclonal anti-
body, which selectively induces depletion of B cells through
direct stimulation of apoptosis, antibody-dependent cyto-
toxicity and complement-dependent cytotoxicity.7 The ﬁrst
report on the use of RTX in inducing remission of SV was
published in 2001 by Speck et al.8 Since then, multiple case
reports and studies were published, including two  large,
controlled trials (RITUXVAS and RAVE) that demonstrated
non-inferiority of induction therapy with RTX compared to
conventional therapy with CYC.9,10 The RITUXVAS study was
published in 2010 by Jones et al., including 44 patients with
newly diagnosed AAV with renal involvement without prior
treatment; these patients were randomized into two  groups,
CYC and RTX.9 The results of the RAVE study were recently
published by Specks et al. and included 197 patients in a
multicenter, randomized, double-blind non-inferiority study
that compared RTX with daily oral CYC for induction of
remission of AAV.10 The authors concluded for non-inferiority
of RTX versus CYC for induction of remission,9,10 and RTX
appears to be more  effective in cases of relapse.10 However,
contrary to what was anticipated, there were no signiﬁcant
differences in serious adverse event rates between these two
groups.10
Recommendations about indication time for RTX as an
inducer of SV remission vary. The main recommendations
refer to AAV; thus, it is still uncertain whether these can
be extrapolated to ANCA-disease negative phenotypes in
patients with GEPA, GPA and MPA or other forms of SV.
There are no comparative data on cost-effectiveness between
RTX and CYC. In general, RTX is indicated as ﬁrst choice
when the treatment aim is trying to avoid the adverse events
related to CYC, especially in young patients with reproduc-
tive aspirations.3,11 This matter was decisive for the deﬁnition
of conduct for patient 5, a 25-year old childless male, who
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was initially treated with RTX. Other situations in which CYC
must be avoided include a high cumulative dose, hypersen-
sitivity and high risk of malignancy.3,11 Another consistent
indication of RTX is for rescue therapy in patients refractory
to conventional therapy due to intolerance or unsatisfac-
tory response; this occurs in 13–30% of cases,11 including
patients 1, 2, 3 and 7 described in this paper, with the ﬁrst
of them due to pharmacological scheme intolerance and the
other due to poor responses. patient 4 received her initial
treatment with a two-week corticoid pulse and an empir-
ical regimen for tuberculosis, with severe evolution; thus,
this patient was subjected to an induction with RTX. Appar-
ently RTX shows better results in patients with relapsing
disease and can be recommended as ﬁrst choice in these
cases.11
Patients 1, 3, 4, 6 and 7 were subjected to four infusions of
RTX, 375 mg/m2 per dose, at 1-week intervals, while patients 2
and 5 received two biweekly infusions of 1 g. Different infusion
schemes may be used for induction of remission in patients
with SV. The main evidence refers to lymphoma protocol,
375 mg/m2/week for 4 weeks, used by most studies, including
RITUXVAS and RAVE.9,10 A minority of authors opted by the
scheme commonly used in rheumatoid arthritis, with an infu-
sion of two doses of 1 g intravenously at an interval of 15 days.
The protocols used for lymphoma and rheumatoid arthritis
appear to be equally effective in AAV, being non-inferior to
conventional therapy.11 A retrospective multicenter study of
65 patients conducted by Jones et al. showed no signiﬁcant
difference between the remission rates for both schemes (81%
with lymphoma protocol versus 75% with rheumatoid arthritis
protocol).11
Although there is convincing evidence that RTX is an effec-
tive alternative for induction and maintenance of remission of
AAV, its role in patients with ANCA-negative SV is still uncer-
tain. The fact that even patients 1, 4 and 6 described in this
paper, besides previous reports,12,13 all with ANCA-negative
subjects, have shown satisfactory responses during induction
therapy suggests that RTX may play a role even in the absence
of such antibodies, acting through other pathogenic mech-
anisms related to B cells, for instance, a possible inﬂuence
on the process of antigen presentation and co-stimulation of
B-cell dependent T cells.7
Less signiﬁcant evidence has been presented as to the role
of RTX in the treatment of patients with PAN. Studies suggest
that in most cases the pathogenesis of PAN are associated
with circulating immune complex deposition and/or vascu-
lar formation in situ, comprised by HBe antigen and speciﬁc
antibodies. These factors then induce the complement cas-
cade activation and monocyte and neutrophil recruitment.5
Thus, the introduction of RTX as a possible therapeutic agent
for patients with PAN is based on the depletion of antibody-
producing B-cells.7 There is no information available in the
literature on randomized trials comparing standard induction
therapy versus RTX in patients with PAN, although isolated
reports point to satisfactory results in selected cases,14,15 such
as with patient 2, who reached complete remission despite the
severe activity of a disease refractory to conventional therapy,
requiring her intensive care unit admission for ventilatory and
hemodynamic support. 0 1 5;5 5(6):531–535
Current knowledge involving therapies for SV remission
induction points to a constant need to develop increasingly
effective and safe therapeutic regimens. With the introduction
of RTX as an alternative to CYC in refractory cases, or in those
patients whom conventional therapy should be avoided, there
was a signiﬁcant increase in published rates of successful
induction of remission. However, short and long term adverse
events associated with available schemes continue causing a
major concern. The cases described in this paper corroborate
the data in the literature, and RTX is a good alternative for
induction of remission in refractory patients or in those with a
contraindication to CYC scheme. Randomized trials with rep-
resentative samples are needed to conﬁrm assumptions about
the efﬁcacy and safety of RTX in patients with PAN or GPA and
ANCA-negative MPA.
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